Dr. Davidsen is vice president of oncology discovery in AbbVie’s R&D organization, where he is responsible for discovery efforts across all oncology programs and sites. Prior to AbbVie’s separation from Abbott, Dr. Davidsen served as Divisional Vice President, Cancer Research. He joined the company in 1986 as a research scientist and has held various positions of increasing responsibility in the discovery organization. Dr. Davidsen has been a critical leader in building AbbVie’s oncology pipeline, directing research teams and partnerships that have led to more than 300 oncology trials across a broad range of hematologic and solid tumor indications, and multiple FDA approvals. He has more than 70 scientific publications across a diverse range of topics including metalloproteinase inhibitors, kinase inhibitors and the discovery of histone deacetylase inhibitors. Dr. Davidsen is a member of AbbVie’s R&D Senior Discovery Leadership Team and the AbbVie Oncology Therapeutic Area Strategy Council. He earned his bachelor’s degree in Chemistry from University of Maryland and Ph.D. in Organic Chemistry from the University of Texas, Austin. He held a post-doctoral position at the University of California, Berkeley before joining Abbott/AbbVie.